Eye Infection Treatment Market Size & Share Analysis - Growth, Trends, And Forecasts (2024 - 2029)

Global Eye Infection Treatment Market Analysis

The Global Eye Infection Treatment Market size is estimated at USD 7.86 billion in 2024, and is expected to reach USD 9.47 billion by 2029, growing at a CAGR of 3.79% during the forecast period (2024-2029).

Major factors such as the increasing incidence and prevalence of eye-related disorders, rising R&D pertaining to the development of novel drugs, and increasing research and development programs are expected to propel the growth of the eye infection treatment market during the forecast period.

The growing prevalence of diabetes mellitus is a significant driver for eye infections such as diabetic retinopathy and endophthalmitis, increasing the demand for effective treatments. For instance, according to a report published by the Investigative Ophthalmology and Visual Science Journal in December 2023, the increased prevalence of diabetes mellitus and diabetic retinopathy (DR) worldwide led to a significant increase in vision-related complications, with over 103 million individuals affected by DR; projections indicate a rise to 161 million by 2045. Technological advancements in screening methods, such as AI-based systems and improved treatments like intravitreal therapy, reduce DR progression and associated blindness in certain regions. These factors drive the demand for more effective treatment options, contributing to the expansion of the eye infection treatment market.

According to a report published by the American Journal of Emergency Medicine in September 2023, postoperative endophthalmitis accounted for 0.04–0.3% of cataract surgeries and 0.2% of glaucoma surgeries, with a 10% chance of poor visual outcomes. The increasing incidence of postoperative endophthalmitis following cataract and glaucoma surgeries, along with its associated risk of poor visual outcomes, is driving the demand for advanced eye infection treatments. Risk factors such as ocular trauma, surgeries, and conditions like diabetes increase the likelihood of infection. These factors have led to the increased demand for eye infection treatments, driving market expansion as healthcare providers address these risks.

Autoimmune disorders like dry eye syndrome and uveitis are contributing to chronic inflammation and heightened infection risks. The aging global population further exacerbates the issue, with older individuals being more susceptible to infections due to weakened immune systems and age-related eye conditions. These combined factors underscore the rising need for advanced eye infection treatments.

Advancements in novel technologies have significantly enhanced the treatment of eye infections and other ocular conditions. For instance, in July 2023, Tarsus Pharmaceuticals Inc. announced the approval of XDEMVY (lotilaner ophthalmic solution) 0.25% by the US Food and Drug Administration (FDA) for the treatment of Demodex blepharitis. XDEMVY, previously referred to as TP-03, was the first FDA-approved therapy specifically targeting Demodex mites, the underlying cause of Demodex blepharitis. Such advancements in novel therapies targeting specific causes of eye infections are driving the growth of the eye infection treatment market by addressing previously unmet clinical needs.

Public health campaigns and educational initiatives have increased awareness of eye health, motivating individuals to seek medical care sooner and avoid the risks of untreated infections. The development of novel therapeutic agents, such as topical antibiotics, antiviral drugs, and antifungal medications, has introduced more effective treatment options for various eye infections. Additionally, innovations in surgical techniques, including laser therapy and microincision cataract surgery, have minimized complications and improved overall patient outcomes.

The increasing prevalence of eye-related disorders, advancements in technology, and the development of novel therapeutic agents are driving the demand for more effective eye infection treatments, contributing to market growth.

However, the loss of patents and side effects of some eye infection treatments are restraining the growth of the eye infection treatment market.

Global Eye Infection Treatment Market Trends

The Fungal Keratitis Segment is Expected to Witness Significant Growth Over the Forecast Period

Global Eye Infection Treatment Industry Segmentation

Eye infections occur when harmful microorganisms affect any part of the eyeball or surrounding area. This includes the clear front surface of the eye (cornea) and the thin, moist membrane lining the outer eye and inner eyelids (conjunctiva). Various methods are used to treat eye infections.

The eye infection treatment market is segmented by drug class, indication, dosage, and geography. The drug class segment is further divided into antibiotics, antivirals, antifungals, antihistamines, corticosteroids, and glucocorticoids. The indication segment is further divided into conjunctivitis, keratitis, endophthalmitis, blepharitis, stye or sty (hordeolum), uveitis, cellulitis, and ocular herpes. The dosage segment is further divided into eye drops, tablets, ophthalmic ointments, and others. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for all the above segments.